Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Issued (2016 - 2025)

Historic Shares Issued for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $39.5 million.

  • Altimmune's Shares Issued rose 2832949.64% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 1412149.53%. This contributed to the annual value of $10.0 million for FY2024, which is 8845.97% down from last year.
  • Latest data reveals that Altimmune reported Shares Issued of $39.5 million as of Q3 2025, which was up 2832949.64% from $37.8 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Shares Issued peaked at $121.0 million during Q4 2022, and registered a low of $38000.0 during Q2 2024.
  • In the last 5 years, Altimmune's Shares Issued had a median value of $13.2 million in 2023 and averaged $22.2 million.
  • As far as peak fluctuations go, Altimmune's Shares Issued plummeted by 9971.25% in 2024, and later skyrocketed by 9943421.05% in 2025.
  • Quarter analysis of 5 years shows Altimmune's Shares Issued stood at $12.5 million in 2021, then surged by 871.19% to $121.0 million in 2022, then plummeted by 99.58% to $510000.0 in 2023, then skyrocketed by 1791.76% to $9.6 million in 2024, then soared by 309.59% to $39.5 million in 2025.
  • Its Shares Issued stands at $39.5 million for Q3 2025, versus $37.8 million for Q2 2025 and $34.7 million for Q1 2025.